BTIG analyst Mark Massaro lowered the firm’s price target on MDxHealth (MDXH) to $6 from $8 and keeps a Buy rating on the shares. The company is an attractive small-cap growth and value stock and a one-stop-shop in personalized prostate diagnostics testing, though the firm is updating its model to bake in some dilution from MDxHealth’s recent $40M public offering, the analyst tells investors in a research note.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks